A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b (PEG-Intron)and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma.

Trial Profile

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b (PEG-Intron)and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2014

At a glance

  • Drugs Dorgenmeltucel-L (Primary) ; Peginterferon alfa-2b
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2012 Results were presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), and in a NewLink Genetics media release.
    • 30 Mar 2012 Status changed from active, no longer recruiting to completed, as reported in a NewLink Genetics Corporation media release.
    • 31 May 2011 Results will be presented at the 47th Annual Meeting of the American Society of Oncology (ASCO-2011).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top